Carasent (LSE:0H9M) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

0H9M Overzicht aandelen

Provides cloud based electronic health record solutions to the health care industry in Sweden, Norway, and internationally.

Over het bedrijf

0H9M fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	2/6

Beloningen

Verhandeld tegen 54.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 112.62% per jaar groeien

Risicoanalyse

Het dividend van 11.54% wordt niet goed gedekt door de winst of de vrije kasstromen

Aandelen zijn zeer illiquide

Carasent ASA Concurrenten

Instem

AIM:INS

UK£199.6m

Intelligent Ultrasound Group

AIM:IUG

UK£36.0m

Renalytix

AIM:RENX

UK£13.7m

Cambridge Cognition Holdings

AIM:COG

UK£14.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Carasent
Historische aandelenkoersen
Huidige aandelenkoers	NOK 14.33
52 Week Hoogtepunt	NOK 16.00
52 Week Laag	NOK 10.00
Bèta	0.52
11 maand verandering	0%
3 maanden verandering	0.31%
1 Jaar Verandering	-9.10%
33 jaar verandering	-61.90%
5 jaar verandering	n/a
Verandering sinds IPO	88.51%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0H9M	GB Healthcare Services	GB Markt
7D	0%	0.2%	-0.8%
1Y	-9.1%	26.1%	9.2%

Rendement versus industrie: 0H9M presteerde slechter dan de UK Healthcare Services -sector, die het afgelopen jaar een rendement van 17.2 % opleverde.

Rendement versus markt: 0H9M presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 9.7 % opleverde.

Prijsvolatiliteit

Is 0H9M's price volatile compared to industry and market?
0H9M volatility
0H9M Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van 0H9M is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0H9M in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	165	Daniel Ohman	carasent.com

Carasent ASA Samenvatting

Hoe verhouden de winst en inkomsten van Carasent zich tot de beurswaarde?
0H9M fundamentele statistieken
Marktkapitalisatie	NOK 1.15b
Inkomsten(TTM)	-NOK 10.39m
Inkomsten(TTM)	NOK 254.01m

4.5x

P/S-verhouding

-111.1x

Koers/Winstverhouding

Is 0H9M overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0H9M resultatenrekening (TTM)
Inkomsten	NOK 254.01m
Kosten van inkomsten	NOK 43.80m
Brutowinst	NOK 210.21m
Overige uitgaven	NOK 220.60m
Inkomsten	-NOK 10.39m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Oct 24, 2024

Winst per aandeel (EPS)	-0.14
Brutomarge	82.76%
Nettowinstmarge	-4.09%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0H9M op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

11.5%

Huidig dividendrendement

-225%

Uitbetalingsratio

0H9M Overzicht aandelen

Beloningen

Risicoanalyse

Carasent ASA Concurrenten

AIM:INS

UK£199.6m

AIM:IUG

UK£36.0m

AIM:RENX

UK£13.7m

AIM:COG

UK£14.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Independent Director recently bought kr100k worth of stock

Recent updates

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Carasent Asa Approves Dividend

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Chief Executive Officer recently bought kr96k worth of stock

High number of new and inexperienced directors

Chief Executive Officer recently bought kr97k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Carasent ASA Samenvatting

4.5x

-111.1x

Inkomsten en omzet

Dividenden

11.5%

-225%